SanBio Company (4592) Q1 2025 earnings summary

Executive summary

• Focused on advancing SB623 regenerative cell therapy, with regulatory deliberations for marketing approval scheduled in June 2024 in Japan.

• Recorded a net loss attributable to owners of parent of ¥144 million for the quarter, a significant improvement from a ¥626 million loss in the same period last year.

• Operating loss narrowed to ¥666 million from ¥1,461 million year-over-year, aided by ¥767 million in foreign exchange gains.

Financial highlights

• Operating revenue for the quarter was zero; operating loss was ¥666 million, down from ¥1,461 million year-over-year.

• Ordinary income turned positive at ¥91 million, compared to a loss of ¥937 million in the prior year.

• Net loss per share improved to ¥2.12 from ¥9.68 year-over-year.

• Comprehensive income was negative ¥883 million, compared to negative ¥1,068 million last year.

Outlook and guidance

• No revisions to the previously announced full-year forecast: net loss of ¥3,359 million and net loss per share of ¥49.45 expected.

• No dividend is planned for the fiscal year.